The Trump administration launched a formal trade investigation into Germany Thursday over drug pricing policies that U.S. officials say force American families to subsidize cheaper medications for Europeans.
U.S. Trade Representative Jamieson Greer opened the probe under Section 301 of the Trade Act, which allows the president to impose tariffs or other penalties on countries deemed to have unfair trade practices. The move targets Germany’s proposed healthcare overhaul, which would slash pharmaceutical spending through steeper discounts demanded from drugmakers.
“President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,” Greer said in a statement. He called Germany’s cost-cutting legislation “a serious step backwards.”
Germany’s Healthcare Crackdown Triggers U.S. Response
Germany proposed overhauling its health insurance system in April to control public spending as healthcare costs have climbed sharply in recent years. The reforms include higher mandatory discounts that insurance funds can demand from pharmaceutical companies.
Multiple drugmaker executives have warned they may pull new medicines from the German market or delay launches there in response to the pricing pressure. The U.S. investigation suggests the Trump administration views those cost controls as Germany offloading research expenses onto American consumers, who typically pay far more for the same medications.
What It Means for Drug Prices at Home
The pharmaceutical industry has long argued that high U.S. drug prices fund the research and development that produces new treatments, while countries with government-controlled healthcare systems pay bargain rates. Americans pay roughly three times what Europeans pay for identical prescription drugs, according to industry data.
The investigation could lead to tariffs on German goods if the administration determines the pricing policies violate trade rules. Whether that would lower drug costs for American families remains unclear—pharmaceutical companies have resisted domestic price controls while citing the need to recoup development costs from somewhere.
The probe puts additional pressure on Germany as it fast-tracks the healthcare legislation through its parliament. U.S. officials will now gather evidence on how the pricing policies affect American drug companies and patients, a process that typically takes several months before any action.
Key Points
- Trump administration opened formal trade probe into Germany’s pharmaceutical pricing policies
- Germany’s proposed healthcare reforms would force deeper discounts from drugmakers to control costs
- Americans pay roughly three times what Europeans pay for identical prescription drugs
https://www.cnbc.com/2026/06/19/us-tariff-probe-germany-drug-pricing-policies-mfn.html – June 19, 2026
